The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis
Open accessAbstract
BACKGROUND: Tuberculosis is the leading killer of patients with human immunodeficiency virus (HIV) infection. Preventive therapy is effective, but current regimens are limited by poor implementation and low completion rates. METHODS: We conducted a randomized, open-label, phase 3 noninferiority trial comparing the efficacy and safety of a 1-month regimen of daily rifapentine plus isoniazid (1-month group) with 9 months of isoniazid alone (9-month group) in HIV-infected patients who were living in areas of high tuberculosis prevalence or who had evidence of latent tuberculosis infection. The primary end point was the first diagnosis of tuberculosis or death from tuberculosis or an unknown cause. Noninferiority would be shown if the upper limit of the 95% confidence interval for the between-group difference in the number of events per 100 person-years was less than 1.25. RESULTS: A total of 3000 patients were enrolled and followed for a median of 3.3 years. Of these patients, 54% were women; the median CD4+ count was 470 cells per cubic millimeter, and half the patients were receiving antiretroviral therapy. The primary end point was reported in 32 of 1488 patients (2%) in the 1-month group and in 33 of 1498 (2%) in the 9-month group, for an incidence rate of 0.65 per 100 person-years and 0.67 per 100 person-years, respectively (rate difference in the 1-month group, -0.02 per 100 person-years; upper limit of the 95% confidence interval, 0.30). Serious adverse events occurred in 6% of the patients in the 1-month group and in 7% of those in the 9-month group (P = 0.07). The percentage of treatment completion was significantly higher in the 1-month group than in the 9-month group (97% vs. 90%, P<0.001). CONCLUSIONS: A 1-month regimen of rifapentine plus isoniazid was noninferior to 9 months of isoniazid alone for preventing tuberculosis in HIV-infected patients. The percentage of patients who completed treatment was significantly higher in the 1-month group. (Funded by the National Institute of Allergy and Infectious Diseases; BRIEF TB/A5279 ClinicalTrials.gov number, NCT01404312.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chesney, M. A., Ickovics, J. R., Chambers, D. B., Gifford, A. L., Neidig, J., Zwickl, B., Wu, A. W., & PATIENT CARE COMMITTEE & ADHERENCE (2000) · AIDS Care · doi:10.1080/09540120050042891 · Cited by 1,428
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa
The TEMPRANO ANRS 12136 Study Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507198 · Cited by 1,242
Treatment of latent tuberculosis infection in HIV infected persons
Akolo, C., Adetifa, I., Shepperd, S., & Volmink, J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000171.pub3 · Cited by 713
New Regimens to Prevent Tuberculosis in Adults with HIV Infection
Martinson, N. A., Barnes, G. L., Moulton, L. H., Msandiwa, R., Hausler, H., Ram, M., McIntyre, J. A., Gray, G. E., & Chaisson, R. E. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1005136 · Cited by 385
Self-citationIsoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study.
De, K., Snider, D. E., & Caras, G. J. (1978) · PubMed · doi:10.1164/arrd.1978.117.6.991 · Cited by 368
Halsey, N. A., Coberly, J. S., Desormeaux, J., Losikoff, P., Atkinson, J., Moulton, L. H., Contave, M., Johnson, M., Davis, H., Geiter, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)06532-x · Cited by 270
Self-citationRangaka, M. X., Wilkinson, R. J., Boulle, A., Glynn, J. R., Fielding, K., van Cutsem, G., Wilkinson, K. A., Goliath, R., Mathee, S., Goemaere, E., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60162-8 · Cited by 262
Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa
Hakim, J., Musiime, V., Szubert, A. J., Mallewa, J., Siika, A., Agutu, C., Walker, S., Pett, S. L., Bwakura-Dangarembizi, M., Lugemwa, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615822 · Cited by 206
Self-citationBadje, A., Moh, R., Gabillard, D., Guéhi, C., Kabran, M., Ntakpé, J.-B., Carrou, J. L., Kouame, G. M., Ouattara, E., Messou, E., et al. (2017) · The Lancet Global Health · doi:10.1016/s2214-109x(17)30372-8 · Cited by 169
Cited by
Furin, J., Cox, H., & Pai, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30308-3 · Cited by 873
Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis
Reid, M., Agbassi, Y. J. P., Arinaminpathy, N., Bercasio, A., Bhargava, A., Bhargava, M., Bloom, A., Cattamanchi, A., Chaisson, R., Chin, D., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01379-x · Cited by 87
Self-citationFeng, J.-Y., Huang, W.-C., Lin, S.-M., Wang, T.-Y., Lee, S. S.-J., Shu, C.-C., Pan, S.-W., Chen, C.-Y., Lin, C.-B., Wei, Y.-F., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.05.009 · Cited by 24
Metadata
- Authors
- Swindells, S., Ramchandani, R., Gupta, A., Benson, C. A., Leon-Cruz, J., Mwelase, N., Jean Juste, M. A., Lama, J. R., Valencia, J., Omoz-Oarhe, A., Supparatpinyo, K., Masheto, G., Mohapi, L., da Silva Escada, R. O., Mawlana, S., Banda, P., Severe, P., Hakim, J., Kanyama, C., Langat, D., Moran, L., Andersen, J., Fletcher, C. V., Nuermberger, E., & Chaisson, R. E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-03-14
- Volume
- 380
- Issue
- 11
- Pages
- 1001-1011
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2921307586
- Cited by
- 363
- References
- 21
- FWCI
- 35.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. https://app.cochat.ai/papers/10.1056/nejmoa1806808
- The paper
- Swindells, S., Ramchandani, R., Gupta, A., Benson, C. A., Leon-Cruz, J., Mwelase, N., Jean Juste, M. A., Lama, J. R., Valencia, J., Omoz-Oarhe, A., Supparatpinyo, K., Masheto, G., Mohapi, L., da Silva Escada, R. O., Mawlana, S., Banda, P., Severe, P., Hakim, J., Kanyama, C., . . . Chaisson, R. E. (2019). One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1806808
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
